What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) received 16 analyst ratings, with 6 being bullish, 4 somewhat bullish, and 6 indifferent. The average 12-month price target for the company is $255.38, a 6.45% decrease from the previous average of $273.00.
September 12, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals received mostly bullish or somewhat bullish ratings from analysts. However, the average 12-month price target has decreased by 6.45%.
The majority of the analyst ratings for Alnylam Pharmaceuticals are bullish or somewhat bullish, indicating a positive outlook for the company. However, the decrease in the average 12-month price target could suggest some uncertainty about the company's future performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100